Novel first-in-class, fatty acid synthase inhibitor, TVB-2640 vs. placebo demonstrates clinically significant reduction in liver fat by MRI-PDFF in NASH: a phase 2 randomised controlled trial (FASCINATE-1)
- Resource Type
- Source
- Journal of Hepatology. 73:S53-S54
- Subject
Hepatology - Language
- ISSN
- 0168-8278